Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Exchange Rate Effect for 4 consecutive years, with -$322000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect fell 147.99% year-over-year to -$322000.0, compared with a TTM value of $28000.0 through Dec 2025, down 93.83%, and an annual FY2025 reading of $28000.0, down 93.83% over the prior year.
  • Exchange Rate Effect was -$322000.0 for Q4 2025 at Zevra Therapeutics, down from $64000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $671000.0 in Q4 2024 and bottomed at -$491000.0 in Q3 2024.
  • Average Exchange Rate Effect over 4 years is $52142.9, with a median of $39500.0 recorded in 2022.
  • The sharpest move saw Exchange Rate Effect plummeted 780.0% in 2023, then surged 219.03% in 2024.
  • Year by year, Exchange Rate Effect stood at $189000.0 in 2022, then soared by 84.66% to $349000.0 in 2023, then soared by 92.26% to $671000.0 in 2024, then crashed by 147.99% to -$322000.0 in 2025.
  • Business Quant data shows Exchange Rate Effect for ZVRA at -$322000.0 in Q4 2025, $64000.0 in Q3 2025, and $658000.0 in Q2 2025.